Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Other Events
10 Apr 24
8-K
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
1 Apr 24
8-K
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
9 Nov 23
8-K
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit
1 Sep 23
8-K
Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
10 Aug 23
8-K
Departure of Directors or Certain Officers
9 Jun 23
8-K
Entry into a Material Definitive Agreement
12 May 23
8-K
Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights
12 May 23
8-K/A
Results of Operations and Financial Condition
4 Apr 23
8-K
Carisma Therapeutics Closes Merger with Sesen Bio
7 Mar 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
12 May 23
POS AM
Prospectus update (post-effective amendment)
12 May 23
S-3
Shelf registration
17 Apr 23
S-3
Shelf registration
17 Apr 23
S-8
Registration of securities for employees
4 Apr 23
425
Business combination disclosure
6 Mar 23
425
Business combination disclosure
28 Feb 23
425
Business combination disclosure
27 Feb 23
425
Business combination disclosure
27 Feb 23
425
Business combination disclosure
22 Feb 23
Proxies
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
DEFA14A
Additional proxy soliciting materials
17 Jun 22
DEFA14A
Additional proxy soliciting materials
9 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
PRE 14A
Preliminary proxy
12 Apr 22
DEFA14A
Additional proxy soliciting materials
7 Apr 21
DEFA14A
Additional proxy soliciting materials
25 Mar 21
DEF 14A
Definitive proxy
25 Mar 21
Other
EFFECT
Notice of effectiveness
16 May 23
EFFECT
Notice of effectiveness
3 May 23
EFFECT
Notice of effectiveness
3 May 23
CORRESP
Correspondence with SEC
28 Apr 23
CORRESP
Correspondence with SEC
28 Apr 23
UPLOAD
Letter from SEC
20 Apr 23
UPLOAD
Letter from SEC
20 Apr 23
EFFECT
Notice of effectiveness
20 Jan 23
SEC STAFF
SEC staff action: Order
20 Jan 23
CORRESP
Correspondence with SEC
19 Jan 23
Ownership
4
John Hohneker
1 Apr 24
3
John Hohneker
1 Apr 24
SC 13G
AbbVie Biotechnology Ltd
13 Mar 24
SC 13D/A
HealthCap VII, L.P.
7 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Richard Steven Morris
2 Feb 24
4
Michael Klichinsky
2 Feb 24
4
Steven Kelly
2 Feb 24
SC 13G/A
Longview Innovation Corp.
2 Feb 24
SC 13D/A
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
26 Jan 24